The Pathologist
  • Explore Pathology

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Molecular Pathology
    • Infectious Disease
    • Digital Pathology

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Oncology
    • Histology
    • Cytology
    • Hematology
    • Endocrinology
    • Neurology
    • Microbiology & Immunology
    • Forensics
    • Pathologists' Assistants
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways
    • Workforce Trends

    Educational Resources

    • Guidelines & Recommendations
    • App Notes
    • eBooks

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Profiles & Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Pathology Captures
Subscribe
Subscribe

False

The Pathologist / Issues / 2026 / February / A New Clue in Developmental Disorders
Neurology Biochemistry and molecular biology Genetics and epigenetics Insights

A New Clue in Developmental Disorders

Bi-allelic mutations associated with intellectual disability and brain abnormalities

02/20/2026 News 2 min read
  • Full Article
  • Summary
  • Takeaways
  • Listen
  • Report
  • Scorecard
  • Quiz
  • Poll

Share

Clinical Scorecard: A New Clue in Developmental Disorders

At a Glance

CategoryDetail
ConditionASTN1-related neurodevelopmental disorders
Key MechanismsBi-allelic variants in the ASTN1 gene disrupt neuronal migration during brain development.
Target PopulationIndividuals with unexplained neurodevelopmental disorders, particularly children.
Care SettingPediatric and neurological practice.

Key Highlights

  • ASTN1 gene variants linked to developmental delay and intellectual disability.
  • Clinical features include autism spectrum disorder, ADHD, and epilepsy.
  • Brain imaging shows variable results, from normal to significant abnormalities.
  • Importance of comprehensive genomic testing for accurate diagnosis.
  • Recognition of complex inheritance patterns in neurodevelopmental disorders.

Guideline-Based Recommendations

Diagnosis

  • Consider comprehensive genomic testing for patients with unexplained neurodevelopmental disorders.

Management

  • Provide genetic counseling and family risk assessment based on ASTN1 findings.

Monitoring & Follow-up

  • Monitor developmental progress and associated clinical features in affected individuals.

Risks

  • Potential for structural brain abnormalities and developmental impairment.

Patient & Prescribing Data

Individuals with bi-allelic variants in the ASTN1 gene.

Management strategies should be tailored based on the spectrum of clinical features.

Clinical Best Practices

  • Utilize exome or genome sequencing to identify rare variants.
  • Consider multilocus pathogenic variation in genetic assessments.
  • Recognize the broad clinical spectrum associated with ASTN1-related disorders.

Related Resources & Content

  • The American Journal of Human Genetics

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.

Newsletters

Receive the latest pathologist news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

Explore More in Pathology

Dive deeper into the world of pathology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

False

Advertisement

Recommended

False

Affiliations:

Specialties:

Areas of Expertise:

Contributions:

False

The Pathologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2026 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.